China-based CStone Pharmaceuticals (HKG: 2616) announced the first patient dosing in a global, multi-center Phase I study for its CS2009, a novel PD-1/VEGF/CTLA-4 trispecific antibody, in Australia. No infusion reactions or other adverse events were observed, marking a promising start to the clinical evaluation of the drug.
Drug Profile
CS2009, an innovative trispecific antibody designed and developed by CStone, combines three clinically validated targets—PD-1, VEGFA, and CTLA-4—to exert multidimensional anti-tumor effects through synergistic actions. Specifically, the drug features:
- Anti-PD-1 activity that reverses T cell exhaustion
- Anti-CTLA-4 activity that promotes T cell activation and proliferation
- Anti-VEGFA activity that blocks tumor angiogenesis and improves the tumor micro-environment (TME)
In the TME, anti-PD-1 and anti-CTLA-4 activities are significantly enhanced by crosslinking with VEGFA. Additionally, CS2009 preferentially blocks PD-1 and CTLA-4 on double-positive tumor-infiltrating T cells while minimizing interference with CTLA-4 regulation in peripheral T cells, potentially offering enhanced efficacy with lower systemic toxicity.
Study Details
The ongoing study is evaluating the clinical value of CS2009 in multiple advanced solid tumors, including non-small cell lung cancer, liver cancer, stomach cancer, endometrial cancer, ovarian cancer, renal cell carcinoma, and cervical cancer. The trial is expected to expand into China and the US in the near term, further assessing the drug’s safety and efficacy profile.-Fineline Info & Tech
Leave a Reply